 |
 |
 |
|
 |
 |
 |
| Course Information for Audit |
This educational site can still be audited free of charge. As an added feature, it is now available for accreditation for pharmacists.
| Course Information for Accreditation |
The following information pertains to accreditation only. Before you proceed to registration, please review the learning objectives and content of the entire site.
Target Audience
Geriatric health-care practitioners
Accreditation
At this time we are offering CE for pharmacists only. The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Site Development Date: June 2000
Site Reviewed: October 2005
CE Release Date: September 2003
CE Expiration Date: September 2006
This program (INDIVIDUAL PROGRAM NUMBER # 203-999-03-686-H01) qualifies for 0.20 CEUs (2.0 contact hours) of continuing pharmacy education. CEUs will be awarded provided that the participant reviews this site and scores 70% or better on the post test that follows. To receive a statement of credit, please complete the examination and evaluation that follows this program. A statement will be awarded and mailed to you within 4-6 weeks.
Site Development Author:
Manju T. Beier, Pharm..D., FASCP
Partner, Geriatric Consultant Resources, LLC
Clinical Associate Professor, College of Pharmacy
University of Michigan, Ann Arbor, Michigan, USA
Learning Objectives
Upon completion of this program, the participant should be
able to:
-
Describe the pathology of Alzheimer's Disease (AD)
-
Describe the economic and social costs of treating patients with AD
-
Discuss the importance of early AD detection and diagnosis
-
Briefly outline the evidence-based recommendations from professional organizations such as the American Academy of Neurology on management of AD
-
Enumerate the neurotransmitter deregulation in AD, specifically the cholinergic hypothesis as it relates to learning and memory
-
Discuss three assessment scales commonly utilized to assess cognition, function, and behavioral disturbances in AD
-
Describe the importance of a thorough assessment for the development of a comprehensive and appropriate treatment plan for an AD patient as he/she progresses through the stages of the disease.
-
Discuss the role of cholinesterase inhibitors and describe their clinical efficacy, mechanisms of action, precautions, administration guidelines, and adverse effects for mild to moderate AD
-
Outline the presently known data on vitamin E. selegiline, estrogen, and ginkgo biloba for the prevention or treatment of AD
-
Enumerate two promising investigational therapies that utilize different pathways other than manipulation of the cholinergic system for the treatment of AD
© 1997-2009 Geriatric Consultant Resources LLC.
All
Rights Reserved.
